MedPacto announced on Jan. 2 that it has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for the combination therapy of Vactosertib and Pembrolizumab (commercially known as Keytruda).This clinical trial targets patients with previo
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Gene cell therapy approaches are gradually gaining renewed attention in response to recent CRISPR and CAR-T news. GCT received keen attention in 2H20 as a viral vector and mRNA-based coronavirus vacc
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Hanmi Pharm delivered consensus-beating OP of W57.5bn for 3Q23, helped by both a higher drug (manufactured by Hanmi) sales portion at Hanmi (non-consolidated) and decreased Beijing Hanmi SG&A expense
TiumBio Co., Ltd. (KRX: 321550. KQ), a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for patients with rare and incurable diseases, today announced that the Phase 1a results of TU2218 will be presented at the 2023 European Society of Medical
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.2Q23 OP to fall short due to high YoY base in MSD vaccine sales We now expect HK inno.N to post sales of KRW207.1bn (-17.8% YoY) and operating profit of KRW11.5bn (-35.0% YoY, operating margin of 5.5%
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410’ (also known as SP0202), evaluating i
SK bioscience announced on May 8 that it has signed a new production agreement for a next-generation Ebola vaccine candidate with global healthcare company MSD.The signing ceremony in Seoul was attended by government officials including Park Min-soo, vice minister of Health and Welfare; Sanat Chatto
We raise our TP on Hanmi Pharm to W430,000. In 1Q23, both consolidated and non-consolidated earnings surpassed consensus, hitting record quarterly figures. Moving ahead, COGS-to-sales ratio should continue to improve thanks to increased sales of Rolontis and other products. We also draw attention to
Samsung Biologics plans to build a fifth plant in Songdo, Incheon, Korea by investing more than 1 trillion won (US$768 million). Previously, the company laid out a plan to build a second campus in October of last year and invest 7.5 trillion won (US$5.8 billion) in the construction of its fifth and
SK bioscience, a global innovative vaccine and biotech company, announced on Jan. 9 that the company's ‘SKYZoster’ shingles vaccine has been approved by the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia.This is the second overseas approval of SKYZoster after Thailand in May 2020.S
Boryung (formerly Boryung Pharmaceutical) announced on Oct. 25 that it has signed an asset acquisition agreement for ‘Alimta (API: pemetrexed)’, a non-small cell lung cancer (NSCLC) treatment, with Eli Lilly and Co. The completion of this transaction is subject to customary regulatory reviews and cl
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and sehunjang@shinhan.com, respectively. – Ed. Positive clinical data for HER2 ADC presented at the World ADCAt the World ADC 2022 conference held on September 7 (local time), there was an announcement
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 2Q22 sales of W316.5bn and OP of W29.6bn, with OP coming in slightly below our estimate. Beijing Hanmi led consolidated OP growth, booking OP of W17.1bn. The strength
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Although the global bio sector index continues to be sluggish, we believe it will be important to pay close attention to global clinical trial data for ADC and KRAS inhibitors at 2022 ASCO (Jun 3~7).
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 1Q22 sales of W321.1bn and OP of W38.7bn, in line with our estimates, thanks to Beijing Hanmi and business normalization amid the easing of the Covid-19 pandemic. Glob
The author is an analyst of NH Investment & Securities. She can be reached at mj27@nhqv.com. -- Ed. HK inno.N’s OP fell 50% y-y in 4Q21 on high-base burden. But, earnings at its cosmetics division are set to improve in earnest going forward on client portfolio diversification, domestic cosmetics bus
Hanmi Pharmaceutical announced on Jan. 20 that it will speed up the production of a generic version of Merck & Co.'s COVID-19 pill, molnupiravir (product name: Lagevrio), for supply to 105 low- and middle-income countries.Hanmi Pharmaceutical is one of the three Korean generic drug manufacturers
Hanmi Pharmaceutical announced on Nov. 17 that its CCR4 target immuno-cancer drug "FLX475," which is under joint development with Rapt and MSD of the United States, has reduced the size of a tumor metastasized to a gastric cancer patient by 58 percent.Hanmi Pharmaceutical presented a poster introduc
The author is an analyst of KB Securities. She can be reached at shinay.park@kbfg.com. -- Ed. Revise down TP to KRW65,000; Additional downside limited We maintain BUY on Kolmar Korea, but revise down our TP by 7% to KRW65,000. We have lowered 2021E/2022E/2023E OP by 17%/9%/4% as we reflect downward